Using an evolutionary epidemiological model of pandemics to estimate the infection fatality ratio for humans infected with avian influenza viruses

Joshua Mack[1], Michael Li[2,3], Amy Hurford[1,4],

[1]Department of Biology, Memorial University, St. John's, Newfoundland and Labrador, Canada A1B 3X9

[2]Modelling Hub, Science and Policy Integration Branch, Public Health Agency of Canada, Guelph, Ontario, Canada N1H 7M7

[3]Department of Mathematics and Statistics, McMaster University, Hamilton, Ontario, Canada L8S 4L8

[4]Department of Mathematics and Statistics, Memorial University, St. John's, Newfoundland and Labrador, Canada A1B 3X9

Keywords: Avian Influenza, Pandemic, Zoonotic Spillover, Human Infection, Mathematical Model, Infection Fatality Ratio, Evolutionary Epidemiology

Abstract

The risk of highly pathogenic avian influenza infection to humans is challenging to estimate because many human avian influenza virus (AIV) infections are undetected as they may be asymptomatic, symptomatic but not tested, and as contact tracing is difficult because human-to-human spread is rare. We derive equations that consider the evolutionary mechanisms that give rise to pandemics and are parameterized to be consistent with records of past pandemics. We estimate that thousands of human AIV infections occur worldwide in an average year and estimate the infection fatality ratio as 32 deaths per 10,000 infections (95% confidence interval: [9.6, 75]). We estimate that preventing 20% of animal-to-human influenza spillovers annually would delay pandemic emergence by an average of 9.4 years. There is a high level of uncertainty in our estimates due to the few records of past pandemics, but even so this infection fatality ratio is comparable to SARS-CoV-2 during the recent pandemic and is higher than seasonal human influenza. Preventing human infections with AIV is necessary given the high risk of severe outcomes to individuals and to reduce the risk of pandemics occurring in the future.

1.   Introduction

The recent spread of highly pathogenic avian influenza (HPAI) in animals poses a risk to humans both individually, due to the risk of avian influenza virus (AIV) infections that result in severe disease, and collectively, due to the risk that AIV adapts to transmit effectively in humans and causes a pandemic. In 2022, HPAI spread across North America and caused mass mortality among wild birds in Eastern Canada with tens of thousands reported sick or dead [1]. As of March 2024, an HPAI outbreak in U.S. poultry and cattle had infected 71 people and was

ongoing [2]. HPAI has not yet adapted to spread well in humans, and of these recent infections there is no evidence of ongoing human-to-human spread [3]. AIV poses a risk to humans individually, as 986 human cases and 473 deaths have been reported around the world since 2003 [4], and collectively, since pandemic flu (in humans) has arisen due to spillover and adaptation of AIV strains about seven times in the last three centuries [5;6;7]. In this study, we will estimate the number of human infections with AIV that occur annually, estimate the infection fatality ratio (IFR) of human AIV infections, and determine how preventing zoonotic spillovers of AIV to humans would delay a future pandemic.

The transmissibility of AIV from animals-to-humans, human-to-human, and the pathogenicity of AIV infections in humans depends on characteristics of the influenza virus. The influenza virus is made of two proteins: hemagglutinin (HA) and neuraminidase (NA). HA binds to sialic acid whose presence and location varies between species which is a major reason for host specificity [8]. There are many (AIV) subtypes (e.g. H5N1, H7N3 and H9N2) with H5N1 being highly pathogenic [9]. Zoonotic spillover refers to the spread of a pathogen from animals to humans [10]. For any zoonotic spillover, the "introduced" strain has not yet evolved to spread from human-to-human but can evolve into an "adapted" strain that spreads between humans and may ultimately cause a pandemic [11;12].

H5N1 emerged in Asia in the late 1990s and since 2003, 986 human cases have been reported around the world with 473 deaths, corresponding to a case fatality ratio of 48% [9;4]. Yet, the case fatality ratio (the number of deaths per case) likely does not describe the risk that HPAI poses to humans, as only some infections are reported as cases, and many human infections are undetected as they may be asymptomatic or symptomatic but not tested. In addition, as there are few secondary infections in humans [13] contact tracing to detect infections is usually not possible. By combining observations describing the occurrence of pandemics in the past with a model that describes the epidemiological and evolutionary processes that occur when an animal strain of influenza adapts to cause a pandemic, we can estimate how many human influenza infections of zoonotic origin are occurring annually. The IFR is the number of mortalities per infection [14] and more accurately quantifies the risk of a severe outcome occurring in a person that is infected with HPAI. We will use our approach to estimate the IFR of AIV in humans, which can be understood as a historical average that is also an average across the different AIV subtypes.

To develop the model to estimate the annual number of human AIV infections from the historical rate of pandemics, we adapt the approach of Day et al., 2006 [15] who estimated the minimum annual number of human AIV infections. Instead of using analytical approximations to calculate the *minimum* annual number of human AIV infections as was done in [15], we use numerical methods to estimate the *mean* annual number of human AIV infections. Following [15], we develop a stochastic model that describes the epidemiological and evolutionary processes that give rise to an influenza pandemic of zoonotic origin. The quantities that we use to predict the annual probability of a pandemic are the number of humans infected by zoonotic

spillovers, the transmissibility of AIV in humans, and the probability of, and epidemiological characteristics that arise from, evolutionary change.

The benefit of preventing human infections with AIV is not only to the individual, as can be quantified by the IFR, but also to reduce the chance that evolutionary change occurs resulting in a pandemic. We use our modelling approach to estimate the effect of preventing human infections with AIV on delaying the time until the next pandemic. Previous studies have modelled the transmission of HPAI between birds and mammals [16;17], HPAI spillover to humans [18], and the human-human transmissibility of HPAI using outbreak data [19]. Our approach overcomes the challenge of limited surveillance to detect asymptomatic human AIV infections.

2. Methods
(a) Model formulation

We follow the methodology described in [15] and use a multitype branching process to model human infections with a genotype, i, of an AIV. Given σ different AIV genotypes, each that are circulating in non-human animal populations with frequencies, $\rho_1, \rho_2, \ldots, \rho_\sigma$, then the probability mass function for the number of human infections with AIV is,

$$P(K_1 = k_1, K_2 = k_2, \ldots, K_\sigma = k_\sigma) = P\left(N_h = \sum_{i=1}^{\sigma} k_i \frac{1}{1 - R_{0,i}}\right)$$
$$= \sum_{n_z} P(N_z = n_z) \times \frac{n_z!}{k_1! \, k_2! \ldots k_\sigma!} \rho_1^{k_1} \rho_2^{k_2} \ldots \rho_\sigma^{k_\sigma}. \tag{1}$$

The AIV may have evolved to infect other animals besides birds, and we let n_z be the annual number of zoonotic spillovers (i.e., AIV infections that spread from animals to humans), where N_z is a random variable describing this quantity. We define $R_{0,i}$ as the basic reproduction number of an AIV of genotype i introduced to humans prior to any adaptation. This is the number of secondary human infections generated by a human infected with an AIV in a wholly susceptible human population before any evolutionary change occurs during any of the subsequent human infections whereby the AIV genotype might evolve to be "pandemic-capable". This basic reproduction number, $R_{0,i}$, is required to be less than 1 because it is assumed that the AIV genotype that spills over to humans is not yet adapted to spread between humans [15;11].

The term $\frac{n_z!}{k_1! \, k_2! \ldots k_\sigma!}$ is the possible combinations of numbers of genotypes that make up all the n_z zoonotic spillovers, which is multiplied by the probability of these combinations occurring, $\rho_1^{k_1} \rho_2^{k_2} \ldots \rho_\sigma^{k_\sigma}$, and together these two terms describe the probability mass function of a multinomial distribution, conditioned on a given number of zoonotic spillovers, n_z. The multiplication by the probability of n_z zoonotic spillovers, $P(N_z = n_z)$, and the sum over n_z reflects the law of total probability. The righthand side of equation (1) is the probability that the number of spillovers for each of the genotypes is $K_1 = k_1, K_2 = k_2, \ldots, K_\sigma = k_\sigma$, and this is equated

to the probability mass function for the number of human AIV infections, $P(N_h = n_h)$, that occur for this number of spillovers of each genotype. Specifically, the genotype i is expected to generate $1/(1-R_{0,i})$ human infections [20], there are k_i instances of zoonotic spillover due to genotype i, and the total number of human infections is the sum across all genotypes.

There are different subtypes and clades of AIV and these aspects of influenza virology are represented in our modelling as we consider AIV genotypes, i. Genotypes that have characteristics, such as high transmissibility in humans, may be more likely to be of a particular subtype or clade, but our modelling represents only the diversity in the epidemiological characteristics without associating such characteristics to a particular subtype.

We assume the number of zoonotic spillovers can be modelled by a probability mass function, for example, a Poisson distribution with a mean equal to $\bar{n}_z$, such that,

$$P(N_z = n_z) = \frac{e^{-\bar{n}_z} \bar{n}_z{}^{n_z}}{n_z!}. \tag{2}$$

Substituting equation (2) into equation (1) and calculating the expected value gives the mean number of human infections with AIV that occur annually, $\bar{n}_h$, as,

$$\bar{n}_h = \sum_{n_z} \frac{e^{-\bar{n}_z} \bar{n}_z{}^{n_z}}{n_z!} \sum_{k_1, k_2, \dots, k_\sigma} \left(\frac{n_z!}{k_1! \; k_2! \dots k_\sigma!} \rho_1{}^{k_1} \rho_2{}^{k_2} \dots \rho_\sigma{}^{k_\sigma} \times \sum_{i=1}^{\sigma} k_i \frac{1}{1 - R_{0,i}} \right), \tag{3}$$

$$= \sum \frac{e^{-\bar{n}_z} \bar{n}_z{}^{n_z}}{n_z!} n_z \bar{m} \tag{4}$$

$$= \bar{n}_z \bar{m}. \tag{5}$$

As such, the mean annual number of human infections includes both the zoonotic spillovers and any subsequent human-to-human transmission of AIV. Equation (5) relates the quantity that we aim to estimate, $\bar{n}_h$, to the mean number of zoonotic spillovers of AIV, $\bar{n}_z$, which we will show can be estimated from the historical rate of pandemics. The simplification that occurs in equation (4) is due to the expected value of the function $f(k_i) = k_i \frac{1}{1 - R_{0,i}}$ for a multinomial distribution, which is $n_z \rho_i \frac{1}{1 - R_{0,i}}$. We define $\bar{m} = \sum \rho_i \frac{1}{1 - R_{0,i}}$ as the mean number of human secondary infections in a wholly susceptible population where the mean is calculated across all genotypes, i. The simplification that occurs in equation (5) is due to substituting $\bar{n}_z$ for the expected value of the Poisson distribution.

The probability of a pandemic occurring in any year can be modelled as a random variable Λ with a probability density that is,

$$P\left(\Lambda = 1 - \prod (1 - \pi_i)^{k_i} \right) = \sum_{n_z} \frac{e^{-\bar{n}_z} \bar{n}_z{}^{n_z}}{n_z!} \times \frac{n_z!}{k_1! \; k_2! \dots k_\sigma!} \rho_1{}^{k_1} \rho_2{}^{k_2} \dots \rho_\sigma{}^{k_\sigma}, \tag{6}$$

where π_i is the probability that an infection with the genotype i causes a pandemic and Λ is equated to the event that at least one of the AIV spillovers results in a pandemic. Data describing

the interpandemic periods for seven pandemics that occurred over the last 245 years is used to estimate the annual probability of a pandemic. The annual probability of a pandemic (which will be estimated from data as described in (b)) is equated to the expected value of equation (6), which is

$$\bar{\Lambda} = 1 - \sum_{n_z} P(N_z = n_z) (1 - \bar{\pi})^{n_z}. \tag{7}$$

The mean probability that a human infection with the AIV genotype i results in a pandemic, $\bar{\pi}$, depends on the probability of a pandemic-capable mutation arising from a single human AIV infection, a_i, and the probability that the pandemic-capable mutation is not lost by random chance. This is

$$\bar{\pi} = \sum_{i=1}^{\sigma} \frac{R_{0,i} - 1 - a_i + \sqrt{(R_{0,i} + 1 + a_i)^2 - 4R_{0,i}(1 + a_i(1 - P_i))}}{2R_{0,i}} \rho_i, \tag{8}$$

which is equation 2.1a in [15]. The parameter P_i can be understood in terms of the expected number of secondary infections that the pandemic-capable strain produces in a wholly susceptible population, R_i^*, where $P_i = 1 - 1/R_i^*$ [11] and $R_i^* > 1$ to satisfy the definition of pandemic-capable.

Our derivation in this section is similar to [15] except that we focus on the mean, rather than the minimum, number of human AIV infections (where the latter was the focus of [15]). As such, we have not used any of the approximations that assume the number of zoonotic spillovers, $\bar{n}_z\bar{\pi}$, and the genotypic variance are small.

(b) Generating genotypes and estimating the mean number of zoonotic spillovers from data

We used Latin hypercube sampling (LHS) [21] to generate genotypes indexed $i = 1$ to $\sigma = 1,000$ by sampling from the distributions described in Table 1 (see section A.1 in the appendix for parameter distributions). All influenza A subtypes have the potential to cause the emergence of pandemic strains through reassortment [22] which is the swapping of gene segments between viruses [23] and/or mutation, so we do not specify any particular HA subtype for the sampled genotypes.

Table 1. Distributions used for LHS to generate genotypes.

Distribution	Meaning	Parameterization	Units and constraints	Reference

R_0	Reproduction number in human population of an AIV prior to evolutionary change	Exponential with a mean of 0.05	Unitless, must be between 0 and 1	Assumed
R^*	Reproduction number in human population of a virus that is a reassortment of a human influenza virus and AIV mutation that is pandemic-capable	Triangular from 1 to 1.1 with a maximum of 2	Unitless, must be greater than 1	Assumed
A	Overall probability that a strain with pandemic potential emerges within any single AIV infection in humans	Uniform between 0.000012 and 0.000024	Unitless, must between 0 and 1	[15]

We fit a gamma distribution to data describing the interpandemic periods of the seven influenza pandemics of zoonotic origin that occurred during the past 245 years (Figure 1), with a mean, δ, and scale parameter, θ. The mean annual probability of a pandemic, to be equated with $\bar{\Lambda}$ in equation (7), is $1/\delta$. The gamma distribution was chosen because this distribution describes the inter-event wait times arising from a Poisson process. The fitting was performed using the maximum likelihood approach and was implemented using the bbmle package in R [24].

Figure 1. Timeline of influenza pandemics that occurred over the last two centuries with influenza subtypes (if known) and interpandemic period lengths [5;6;7]

It has been argued that pandemics are becoming more frequent [25]. As such, we also hypothesize that the mean of the interpandemic period is affected by the date of past pandemics, i.e., whereby more recent pandemics may have occurred more frequently. To do this, we let $\delta = \delta_0 + \delta_1 x_d$ where δ_0 and δ_1 are parameters for the intercept and slope of the relationship between the mean interpandemic period and x_d is the number of years since 1781 (the date of the first pandemic we consider). We calculate the likelihood ratio for the model with an effect of recency compared to a model without an effect of recency.

We sampled from our fitted gamma distribution to generate estimates of $\bar{\Lambda}_i$. The sampling approach incorporates uncertainty in the interpandemic period, some of which is because there are only a few influenza pandemics reported that occurred during the last centuries. Our estimation approach does not explicitly consider influenza subtypes because relatively few pandemics have occurred in the past, such that it is not possible to estimate the annual probability of a pandemic due to a particular subtype.

(c) Calculating the distribution of the mean annual number of human AIV infections

We calculated the distribution of the mean annual number of human AIV infections by completing $\sigma = 1,000$ samples of $R_{0,i}$, P_i (calculated as $= 1 - 1/R_i^*$), a_i, and $\bar{\Lambda}_i$. This sampling occurred using the lhs package in R. For all the sampled values of $R_{0,i}$, P_i, and a_i, we calculate $\bar{\pi}$ using equation (8), where the frequency of each genotype is $\rho_i = 1/\sigma$ for all i. We then calculate $\bar{n}_{z,i}$ by equating the sampled value of $\bar{\Lambda}_i$ with $\bar{\Lambda}$ in equation (7) and solving for $\bar{n}_z$, which is the only unknown value (and for this specific realization of the sampling is referred to as $\bar{n}_{z,i}$). The value of $\bar{n}_{z,i}$ is then substituted for $\bar{n}_z$ in equation (5) to estimate one of the values of $\bar{n}_{h,i}$, where all these values together comprise our estimated distribution for the mean annual number of human infections with AIV.

(d) Calculating the IFR and the impact of preventing zoonotic spillovers

We calculate the IFR by estimating the annual number of human mortalities due to AIV as 473 reported human mortalities over the last 23 years [4], which is on average 20.6 deaths per year. The IFR is calculated as the annual number of mortalities, divided by the mean annual number of human infections with AIV as estimated in (c), and is expressed as a percentage. We assume that all human fatalities with AIV are reported.

We also investigate the impact of control measures that reduce the mean number of zoonotic AIV spillovers to humans by a fraction, χ. We modify equation (7) to determine how these control measures impact the annual probability of a pandemic as,

$$\Lambda_\chi = 1 - \sum_{n_z} \frac{e^{-\bar{n}_z(1-\chi)}\bar{n}_z(1-\chi)^{n_z}}{n_z!}(1-\bar{\pi})^{n_z} \tag{9}$$

.

(e) Comparison to previously estimated minimum annual spillovers

We complete an analysis to compare our results with the minimum annual number of zoonotic spillovers implied by the historical interpandemic period as estimated in [15]. For our comparison, we graph the range of the minimum estimates of the annual zoonotic spillovers using equation (2.1b) from [15], which is,

$$\bar{\Lambda} = \frac{\bar{n}_z}{1 - R_0} aP, \tag{10}$$

in our notation. As is assumed in Figure 2 of [15], we consider the minimum and maximum values of a as 0.000012 and 0.000024, the minimum and maximum values of $\bar{\Lambda}$ as 0.007 and 0.076, and we fix $P = 1$. Using this approach, we produce a range for the minimum annual number of zoonotic spillovers as was done in [15].

To estimate an analogous minimum number of zoonotic spillovers using our methodology, we set $P = 1$ for all i, set R_0 to each of 0, 0.2, 0.4, 0.6 and 0.8, and sample from the distributions for the other parameters as described in (b) and (c). Using this approach, we produce a distribution for the minimum annual number of zoonotic spillovers, which we compare to the range that was calculated in [15].

Results

We fitted the gamma distribution to the interpandemic periods of past pandemics (Figure 1) and estimated the mean interpandemic period as $\delta = 38$ years (95% confidence interval: [25, 62]) with $\theta = 8.9$ (95% confidence interval: [2.8, 28.4]). We also fitted a gamma distribution with a mean that depends on the start date of the past pandemics and estimated $\delta_0 = 53.5$ years (95% confidence interval: [28.3, 102.6]), $\delta_1 = -0.14$ years per year (75% confidence interval: [-0.27, -0.03]; standard error: 0.10), and $\theta = 9.2$ (95% confidence interval: [2.7, 31.5]). The likelihood ratio for the model with an effect of recency on the interpandemic period compared to the model without an effect of recency is 1.99 which means that the start date of the interpandemic period

did not have a clear effect on the mean interpandemic period [26] (see Appendix A.2 for additional details). While the effect of recency on the interpandemic period is not clear, other studies argue that pandemics are becoming more frequent [25], and so we consider results that incorporate this effect in our subsequent analyses.

Figure 2. Estimated mean annual number of human infections with AIV (A) and corresponding

IFRs (B). The mean interpandemic period of 38 years corresponds to if there is no effect of recency on the interpandemic period (red line). If we assume an effect of recency on the interpandemic period, then the expected interpandemic period in 1781 is 53.5 years (blue line) and 18.5 years in 2026 (orange line). As the distribution of the mean annual number of human infections with AIV is highly right-skewed these estimates are shown on a logarithmic (base 10) scale.

We sampled from our fitted gamma distribution and created genotypes as described in (c) and evaluated equation (5) to estimate a mean of 6,458 annual human infections with AIV when there is no effect of recency on the interpandemic period (95% confidence interval: [2,737, 21,265]; Figure 2A; red line). This corresponds to an IFR of 20.6/6,458= 0.32% (95% confidence interval: [0.096%, 0.75%]) which is 32 deaths per 10,000 infections (Figure 2B). These estimates are implied by our calculation of the number of human AIV infections based on the assumed evolutionary and epidemiological process, and the interpandemic periods of past seven pandemics. The distribution of annual human AIV infections is highly right-skewed, which means that a very large number of human infections with AIV ($\bar{n}_h > 20{,}000$) is possible, although with low probability (< 0.025), and that the median ($\bar{n}_h = 6{,}458$) is much lower than the mid-point of the interval ranging from the 2.5th to 97.5th percentile.

We also calculate how our estimated number of human AIV infections would be different if pandemics are becoming more frequent. The first pandemic that we consider occurred in 1781 (Figure 1) and from our statistical analysis, we estimate the mean time to the next pandemic in 1781 is 53.5 years. For an interpandemic period of 53.5 years, we calculate an annual mean number of 4,438 human AIV infections (95% confidence interval: [2,115, 11,837]; Figure 2A, blue line). This corresponds to an IFR of 46 deaths (95% confidence interval: [17, 97]) per 10,000 infections (Figure 2B). For the year 2026, we estimate the mean interpandemic period as 18.5 years. For an interpandemic period of 18.5 years, we estimated an annual mean number of 13,169 human AIV infections (95% confidence interval: [6,223, 36,228]; Figure 2A, orange line). This corresponds to an IFR of 16 deaths (95% confidence interval: [5.6, 33]) per 10,000 infections (Figure 2B). Details describing how we calculated the interpandemic period for 1781 and 2026 are provided in appendix A.2.

Figure 3. The mean (solid line) number of years that the next pandemic is delayed when a percentage of animal-human AIV spillovers are prevented, with the dark shading representing the interquartile range and the light shading representing the 95% prediction interval. Negative values correspond to probabilities, that are often small, that the next pandemic occurs sooner.

We used our parameter estimates and sampling approach to understand the impact of preventing zoonotic spillovers on the annual risk of a pandemic as described by equation (9). We estimate that preventing 5%, 20% and 50% of animal-human AIV spillovers would delay pandemic emergence by an average of 2, 9.4 and 37.5 years respectively (Figure 3). As the annual probability of a pandemic occurring is subject to a high level of uncertainty (as modelled by equation 9), there is some chance, often which is small, that a pandemic can occur sooner than the mean time to the next pandemic when there is no prevention of zoonotic spillovers. Our estimates of the effect of preventing zoonotic spillovers on the number of years the next pandemic would be delayed are subject to a high level of uncertainty (Figure 3).

Figure 4. Estimated annual number of zoonotic spillovers of AIV. Grey shaded areas reproduce the results from Figure 2 in [15] and span the 95% support interval of the probability of a pandemic occurring in any given year. Light grey shading is an attack rate of 20% and dark grey shading is an attack rate of 10%. A) shows our estimated distribution of the minimum annual number of zoonotic spillovers (purple shaded curve) and B) shows our estimated distribution of the mean annual number of zoonotic spillovers (purple-yellow shaded curves).

We based our methodology in (a) on [15] but deviated in our approach as we aimed to find the distribution of the mean annual number of human AIV infections rather than the minimum number. We find that our estimates of the minimum annual number of zoonotic AIV spillovers, $\bar{n}_z$ are consistent with [15] (Figure 4A). Our estimates of the mean annual number of zoonotic AIV spillovers, that sample from the distribution for P, are higher (Figure 4B) than both the minimum estimates of [15] (grey shading) and our own minimum estimates (Figure 4A).

3. Discussion

We developed a stochastic model based on epidemiological and evolutionary processes that give rise to pandemics to estimate the number of human infections with AIV that occur each year for the years when a pandemic is not occurring. We estimate that, on average, there are 6,458 annual human infections with AIV worldwide, which is much higher than the 986 human cases reported to date and suggests that many infections are undetected and could be because some humans infected with AIV are asymptomatic or symptomatic but not tested. Based on our estimate of annual AIV infections and the assumption that all AIV deaths in humans are reported, the IFR of 32 deaths per 10,000 infections is much lower than the reported case fatality rate of 48% [4]. The IFR better informs risk of HPAI infection to humans that handle infected wildlife as it includes asymptomatic and undiagnosed individuals [14] and is not biased by the intensity of surveillance

activities. The US Centers for Disease Control and Prevention conducted two studies that support that HPAI infections are often asymptomatic or symptomatic but not tested [27;28]. One study found that 7% of dairy farm workers tested had antibodies to H5, despite not knowing they had been infected and the other found antibodies in 2% of serum samples from bovine veterinarians [13].

Our estimate of an IFR of 32 deaths per 10,000 human infections with AIV, which is 0.32%, is very high but also with a high degree of uncertainty (95% confidence interval [9.6, 75]). For our model that assumes pandemics are becoming more recent, for 2026, we estimate the IFR as lower: 16 deaths (95% confidence interval: [5.6, 33]) per 10,000 human infections with AIV. For reference, the IFR of SARS-CoV-2 variants in 2020-2023 was estimated as 16 deaths per 10,000 infections [29]. Therefore, even with the uncertainty in our estimates, both due to the few observations of pandemics that were considered in estimating the IFR and due to uncertainty in whether pandemics are become more recent, our estimate of the IFR for human infections with AIV is similar to, and possibly higher than, the IFR of SARS-CoV-2 variants during the recent pandemic. For seasonal influenza the IFR has been estimated as 2.9-6.5 deaths per 10,000 infections [30]. Given our estimates, we conclude that the IFR for human AIV infections is higher than that of seasonal influenza.

Given our estimate of a relatively high IFR for human AIV infections, for hunters, trappers, poultry workers, farmers, wildlife officials, veterinarians and other groups that handle wildlife there is a need to be cautious as there is a relatively high chance that human HPAI infections can result in severe infections. The primary virulence mechanism of all H5 viruses involves hemagglutinin (HA), which relies on host proteases for cleavage into two subunits required for cell invasion. In HPAI viruses, a polybasic cleavage site is formed by acquiring multiple basic amino acids. This allows cleavage by furin-like proteases which are distributed more broadly in tissues, enabling systemic infection in birds and mammals, which can result in high pathogenicity [13]. Our estimate of a high IFR for human infections with AIV may have some basis in terms of viral virulence mechanisms of HPAI. Furthermore, HP in HPAI refers to "highly pathogenic" since these viruses have high mortality in wild birds [1].

Efforts to prevent human infections with non-pandemic capable genotypes of HPAI are necessary given the high individual risk of severe outcomes (as measured by the IFR), but also to lower the risk of a pandemic emerging in any given year. We estimate that preventing 20% of animal-to-human AIV spillovers annually would delay pandemic emergence by an average of 9.4 years and preventing 50% of spillovers would delay pandemic emergence by 37.5 years. Measures that prevent the spillover of HPAI to humans include not touching, feeding or handling potentially infected birds or other animals, when contact cannot be avoided wearing gloves and a well-fitted respirator or medical mask, reporting infected animals to the appropriate animal health authority [3], the humane destruction of infected and exposed animals, and strict quarantine and animal movement controls to prevent disease spread [31].

We found that the pandemic start date had no clear effect on the mean interpandemic period. The reason that there is not stronger evidence supporting pandemics occurring more frequently now than in the past, is that there are few observations of pandemics (rather than abundant data that support no effect), and because arguments have been presented for mechanisms that would mean pandemics occur more frequently now. These mechanisms include agricultural expansion, deforestation, urbanization and wildlife trade and consumption. These activities bring wildlife, livestock, and humans into close contact which can lead to zoonotic spillovers, epidemics, and pandemics [25]. Increased global connectivity through international travel, population growth, and climate change further increases the risk of infectious disease outbreaks [32].

A limitation of our work is that we have inferred the number of human AIV infections from assumed evolutionary mechanisms, parameter value distributions, and the historical rate of pandemics, and our analysis includes no verification of these estimates based on diagnostic testing or serological surveys, such that the validity of our estimates depends on our model assumptions. Our modelling assumes that the probability of a pandemic-capable evolutionary change occurring is constant over time, but this is likely not the case. Adaption of HPAI strains to spread between humans might occur due to reassortment that occurs when a human is coinfected with HPAI and human influenza, but this risk of coinfection is variable (Figure 5).

Our approach to estimate the annual number of human AIV infections does not consider the seasonal and wildlife epidemiological dynamics of zoonotic spillovers or the seasonality of human influenza and the probability of a pandemic-capable mutation occurring. Instead, we assume only seasonal averages for these values, which could result in biased estimation due Jensen's inequality, which states that using average values in calculations often results in inaccuracies. We also do not consider the spatial components of AIV spread, such that our estimates are for the number of human AIV infections that occur worldwide, and our modelling approach is not sufficient to inform where these infections might be occurring in any given year, or how these infections could change between years. Future directions of this work include adding temporal and spatial structure to the model to better inform when, and where, our inferred number of human AIV infections are occurring.

Given the recent outbreaks of HPAI virus in animals, it is necessary to communicate the risk to humans and to explain the rationale for preventative measures. One component of risk to hunters, trappers, poultry workers, farmers, wildlife officials, veterinarians and other groups that handle wildlife is the chance that they are handling an infected animal, and initiatives such as AviFluMap and similar projects in the United States and Europe [33], aim to estimate this component of risk. Another component of risk is the probability of a severe outcome given a human AIV infection, and estimating this quantity was the focus of our study. The strength of our work has been to estimate undetected AIV infections by combining sources given the few data that are available to estimate this quantity. These data were past records of pandemics, and this approach is reasonable given that there are few serological surveillance activities to detect

asymptomatic and other untested human AIV infections. We estimate that the IFR of human AIV infections is high relative to human influenza, and possibly SARS-CoV-2, such that individuals that take measures to prevent AIV infections would avoid the high risk of a severe infection. We also show that the value of preventing human AIV infections extends beyond the individual, as preventing human AIV infections delays the emergence of a global pandemic. Our results quantify the value of preventing human AIV infections to both the individual and to society.

Figure 5. The risk of human infection with HPAI depends on the epidemiological dynamics of HPAI spread in wildlife populations including the effect of bird migration. A mutation with

pandemic potential can arise from reassortment. The risk of coinfection with HPAI and human influenza in the Northern Hemisphere depends on the seasonal dynamics of human influenza.

Acknowledgments. AH was supported by a Natural Sciences and Engineering Research Council of Canada Discovery Grant (RGPIN 023-05905) and a Catalyst Grant: Avian Influenza OneHealth Research 'Enhanced tracking of the circulation of and risk from highly pathogenic avian influenza viruses at the human-wildlife interface' from the Canadian Institutes of Health Research. JM, ML, and AH were support by an Atlantic Canada Research in the Mathematical Sciences Collaborative Research Group award. We acknowledge comments on the manuscript from Joseph Baafi, Francis Anokye, Abdou Fofana and Giuseppe Pasqualino.

Appendix

A.1 Parameter distributions

Figure A1 shows the sampled values of the parameters that were used to estimate the mean annual number of human AIV infections, where σ genotypes are created by sampling from plausible trait values.

Figure A1. Sampled values of three parameters, where these samples are the basis for the estimated annual number of human AIV infections shown in Figure 2.

A.2 Distribution of interpandemic periods

For our analysis of the effect of pandemic start date on the mean interpandemic period, we estimate that δ_1 = -0.14 (75% confidence interval: [-0.27, -0.029]). The parameter estimate for δ_1 means that there are 14 years less between pandemics that occur a century later (Figure A2). Based on these estimates, the mean interpandemic period for our earliest record in 1781 is 53.5 years and for the present, which we take to be 2026, the mean interpandemic period is 53.5 - 245 × 0.14 which is about 18.5 years until the next pandemic. To investigate the impact of pandemics occurring more recently in recent times, we consider these interpandemic periods for 1781 and 2026 in Figure 2A.

Figure A2. Effect of pandemic start date on the mean interpandemic period.

References

1. Avery-Gomm S, Barychka T, English M, Ronconi R, Wilhelm SI, Rail J-F, Cormier T, Beaumont M, Bowser C, Burt TV, et al. 2024 Wild bird mass mortalities in Eastern Canada associated with the highly pathogenic avian influenza A(H5N1) virus, 2022. *medRxiv* **15**, e4980. (doi:10.1101/2024.01.05.574233)

2. Centers for Disease Control and Prevention. 2025 *H5 Bird Flu: Current situation*. CDC. See https://www.cdc.gov/bird-flu/situation-summary/index.html (accessed on 20 October 2025).

3. Public Health Agency of Canada. 2025 *Avian influenza A(H5N1): Spread, prevention and risks*. Government of Canada. See https://www.canada.ca/en/public-health/services/diseases/avian-influenza-h5n1/prevention-risks.html (accessed on 20 October 2025).

4. World Health Organization. *2025 Avian Influenza A(H5N1) – Cambodia*. WHO. See https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON575 (accessed on 2 December 2025).

5. Romaniello MP. 2024 The influential influenza: The "Russian catarrh" pandemic of 1781–1782. *Journal of the History of Medicine and Allied Sciences*. 1-16. (doi:10.1093/jhmas/jrae025)

6. Dowdle WR. 1999 Influenza A virus recycling revisited. *Bulletin of the World Health Organization* **77**, 820–828.

7. Hajjar SA, & McIntosh, K. 2010 The first influenza pandemic of the 21st century. *Annals of Saudi Medicine* **30**, 1–10. (doi:10.5144/0256-4947.59365)

8. World Health Organization. 2010 *Virology of human influenza*. WHO. See https://www.who.int/europe/news-room/fact-sheets/item/virology-of-human-influenza (accessed on 20 December 2025).

9. Health Canada. 2025 *Highly Pathogenic Avian Influenza (HPAI) and food safety*. Government of Canada. See https://www.canada.ca/en/services/health/food-safety/highly-pathogenic-avian-influenza-hpai.html (accessed on 9 January 2026).

10. Plowright RK, Ahmed AN, Coulson T, Crowther TW, Ejotre I, Faust CL, Frick WF, Hudson PJ, Kingston T, Nameer PO, O'Mara MT, Peel AJ, Possingham H, Razgour O, Reeder DM, Ruiz-Aravena M, Simmons NB, Srinivas PN, Tabor GM, Tanshi I, Thompson IG, Vanak AT, Vora NM, Willison CE, Keeley ATH. 2024 Ecological countermeasures to prevent pathogen spillover and subsequent pandemics. *Nature Communications* **15**, 2577. (doi:10.1038/s41467-024-46151-9)

11. André JB, Day T. 2005 The effect of disease life history on the evolutionary emergence of novel pathogens. *Proceedings of the Royal Society B: Biological Sciences* **272**, 1949–1956. (doi:10.1098/rspb.2005.3170)

12. Antia R, Regoes RR, Koella JC, Bergstrom CT. 2003 The role of evolution in the emergence of infectious diseases. *Nature* **426**, 658–661. (doi:10.1038/nature02104)

13. Drake JM. 2025 Understanding avian influenza mortality: Three theories could explain why the North American H5N1 epidemic has not been more deadly. *Science* **389**, 1292-1294. (doi:10.1126/science.adx7159)

14. Böttcher L, Xia M, Chou T. 2022 Why case fatality ratios can be misleading: individual- and population-based mortality estimates and factors influencing them. *Physical Biology.***17**, 065003. (doi:10.1088/1478-3975/ab9e59).

15. Day T, André JB, & Park, A. 2006 The evolutionary emergence of pandemic influenza. *Proceedings of the Royal Society B: Biological Sciences* **273**, 2945–2953. (doi:10.1098/rspb.2006.3638)

16. Fatoyinbo H, Tiwari P, Olanipekun PO, Ghosh I. 2025 A mathematical model of HPAI transmission between dairy cattle and wild birds with environmental effects. *Preprint* (doi:10.48550/arXiv.2508.12201)

17. Chang Y, Gonzales JL, Reimert MM, Rattenborg E, de Jong MCM, Conrady B. 2025 Assessing the Spatial and Temporal Risk of HPAIV Transmission to Danish Cattle via Wild Birds. *Preprint* (doi:10.48550/arXiv.2504.12432)

18. Cherian P, Menon GI. 2025 Modelling a potential zoonotic spillover event of H5N1 influenza. *BMC Public Health* **25**, 3983. (doi:10.1186/s12889-025-25358-5)

19. Yang Y, Halloran ME, Sugimoto JD, Longini IM. 2007 Detecting human-to-human transmission of avian influenza A (H5N1). *Emerging Infectious Diseases* **13**, 1348–53. (doi:10.3201/eid1309.070111)

20. Farrington CP, Kanaan MN, Gay NJ. 2003 A primer on the use of probability generating functions in infectious disease modeling. *Infectious Disease Modelling* **3**, 192-248. (doi:10.1016/j.idm.2018.08.001)

21. Blower SM, & Dowlatabadi H. 1994 Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. *International Statistical Review / Revue Internationale de Statistique* **62**, 229. (doi:10.2307/1403510)

22. Webster RG, & Hulse DJ. 2004 Microbial adaptation and change: Avian influenza. *Revue Scientifique et Technique de l'Office International des Épizooties* **23**, 453-465. (doi:10.20506/rst.23.2.1493)

23. Steel J, & Lowen, AC. 2014 Influenza A virus reassortment. *Current Topics in Microbiology and Immunology* **385**, 377–401. (doi:10.1007/82_2014_395)

24. Bolker B, R Development Core Team. 2025 *bbmle: Tools for General Maximum Likelihood Estimation.* GitHub. See https://github.com/bbolker/bbmle (accessed on 20 October 2025).

25. Daszak P, das Neves CG, Amuasi J, Hayman D, Kuiken T, Roche B, Zambrana-Torrelio C, Buss P, Dundarova H, Feferholtz Y, *et al.* 2020 IPBES workshop on biodiversity and pandemics: executive summary. *IPBES*. See https://ipbes.net/pandemics.

26. Deeks JJ, Altman DG. 2004 Diagnostic tests 4: likelihood ratios. *BMJ.* **329**, 168–169. (doi: 10.1136/bmj.329.7458.168)

27. Mellis AM, Coyle J, Marshall KE, Lucero-Obusan C, Kelleher AD, Lehman CW, Tatham L, Fry AM, Wentworth DE, Biggerstaff M, et al. 2024 Serologic Evidence of Recent Infection with Highly Pathogenic Avian Influenza A(H5) Virus Among Dairy Workers — Michigan and Colorado, June–August 2024. *Morbidity and Mortality Weekly Report* **73**, 1004-1009. (doi:10.15585/mmwr.mm7344a3)

28. Leonard J, Harker EJ, Szablewski CM, Margrey SF, Gingrich KF II, Crossley K, Fletcher E, McCreavy CJ, Weis-Torres S, Wang D, et al. 2025 Notes from the Field: Seroprevalence of Highly Pathogenic Avian Influenza A(H5) Virus Infections Among Bovine Veterinary Practitioners — United States, September 2024. *Morbidity and Mortality Weekly Report* **74**, 50-52. (doi:10.15585/mmwr.mm7404a2)

29. Riedmann U, Chalupka A, Richter L, Sprenger M, Rauch W, Krause R, et al. 2025 COVID-19 case fatality rate and infection fatality rate from 2020 to 2023: Nationwide analysis in Austria. *Journal of Infection and Public Health* **18**, 102698. (doi:10.1016/j.jiph.2025.102698)

30. World Health Organization. 2025 *Influenza (seasonal).* WHO. See https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (accessed on 13 December 2025).

31. Canadian Food Inspection Agency. 2025 *Facts about avian influenza*. CFIA. Available at: https://inspection.canada.ca/en/animal-health/terrestrial-animals/diseases/reportable/avian-influenza/facts-about-avian-influenza (accessed on 15 January 2026).

32. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, et al. 2021 Infectious disease in an era of global change. *Nature Reviews Microbiology* **20**, 193–205. (doi:10.1038/s41579-021-00639-z)

33. Ross, T. A., Ryding, S., Lisovski, S., Driessen, J., Mowat, E., Todd, S., Purnell, C., Spence, A., Vitali, S., Yu, H. & Klaassen, M. 2026 AviFluMap: an interactive tool to assess H5N1 avian influenza incursion risk in Australia via migratory birds. *Ecological Informatics* **93**, 103603. (doi:10.1016/j.ecoinf.2026.103603)